JP2009080118A5 - - Google Patents

Download PDF

Info

Publication number
JP2009080118A5
JP2009080118A5 JP2008259812A JP2008259812A JP2009080118A5 JP 2009080118 A5 JP2009080118 A5 JP 2009080118A5 JP 2008259812 A JP2008259812 A JP 2008259812A JP 2008259812 A JP2008259812 A JP 2008259812A JP 2009080118 A5 JP2009080118 A5 JP 2009080118A5
Authority
JP
Japan
Prior art keywords
muramyl dipeptide
protein
adjuvant composition
microparticles
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008259812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009080118A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009080118A publication Critical patent/JP2009080118A/ja
Publication of JP2009080118A5 publication Critical patent/JP2009080118A5/ja
Pending legal-status Critical Current

Links

JP2008259812A 1996-10-10 2008-10-06 ウイルス感染を処置するための組成物および方法 Pending JP2009080118A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2819496P 1996-10-10 1996-10-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP10517749A Division JP2001502315A (ja) 1996-10-10 1997-10-10 ウイルス感染を処置するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2009080118A JP2009080118A (ja) 2009-04-16
JP2009080118A5 true JP2009080118A5 (enExample) 2010-01-28

Family

ID=21842081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10517749A Ceased JP2001502315A (ja) 1996-10-10 1997-10-10 ウイルス感染を処置するための組成物および方法
JP2008259812A Pending JP2009080118A (ja) 1996-10-10 2008-10-06 ウイルス感染を処置するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP10517749A Ceased JP2001502315A (ja) 1996-10-10 1997-10-10 ウイルス感染を処置するための組成物および方法

Country Status (11)

Country Link
US (6) US6043347A (enExample)
EP (1) EP0939835A4 (enExample)
JP (2) JP2001502315A (enExample)
KR (2) KR100667121B1 (enExample)
CN (1) CN1327896C (enExample)
AU (1) AU732809B2 (enExample)
BR (1) BR9712289A (enExample)
CA (1) CA2268372C (enExample)
MX (1) MXPA02010374A (enExample)
NZ (1) NZ334941A (enExample)
WO (1) WO1998015658A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268372C (en) * 1996-10-10 2012-11-27 Probe International Compositions and methods for treating viral infections
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
CN1339319A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
JP2007524609A (ja) * 2003-04-10 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド コンフォメーションに関する変種のプロファイリング、抗体組成物
US7206991B2 (en) * 2003-10-15 2007-04-17 Lsi Logic Corporation Method, apparatus and program for migrating between striped storage and parity striped storage
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
US20060110405A1 (en) * 2004-08-20 2006-05-25 Buckheit Robert W Jr Plasma or serum fraction for treatment and prevention of viral infections and related conditions
NZ587255A (en) * 2005-01-13 2012-03-30 Novartis Vaccines & Diagnostic Elisa assays using prion-specific peptide reagents
EP1855112A1 (en) * 2006-05-10 2007-11-14 Inserm Method for the in vitro screening of compounds inhibiting production of infectious HIV-1 virions
US8200520B2 (en) 2007-10-03 2012-06-12 International Business Machines Corporation Methods, systems, and apparatuses for automated confirmations of meetings
JP5662309B2 (ja) * 2008-04-01 2015-01-28 イネイト・イムノセラピューティクス・リミテッド 腫瘍性疾患を治療するための組成物および方法
CA2719252C (en) * 2008-04-01 2016-01-19 Innate Therapeutics Limited Anti-infective agents comprising muramyl dipeptide microparticles and uses thereof
NZ571665A (en) * 2008-09-30 2011-01-28 Innate Therapeutics Ltd Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
JPWO2010134305A1 (ja) 2009-05-18 2012-11-08 国立大学法人 東京医科歯科大学 Ｈｉｖ立体構造認識抗体誘導ペプチド抗原、及びその合成方法
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
RU2517084C2 (ru) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Способ и средство для ингибирования продукции или усиления элиминации белка р24
CN103502264A (zh) 2011-04-04 2014-01-08 国立大学法人东京医科齿科大学 Hiv立体结构识别抗体诱导肽
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2017093985A1 (en) * 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
CN108997482B (zh) * 2018-08-09 2025-09-09 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
EP3996815A2 (en) * 2019-07-15 2022-05-18 Lausanne University Hospital Hiv binding agents
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5528933A (en) * 1978-08-21 1980-02-29 Dai Ichi Seiyaku Co Ltd Muramyldipeptide dimer
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
CA2025634A1 (en) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
CA2268372C (en) * 1996-10-10 2012-11-27 Probe International Compositions and methods for treating viral infections

Similar Documents

Publication Publication Date Title
JP2009080118A5 (enExample)
Chattopadhyay et al. Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation
Yan et al. Current applications and future prospects of nanotechnology in cancer immunotherapy
Bal et al. Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations
JP2010527906A5 (enExample)
CN103037898B (zh) 呼吸道合胞病毒抗原组合物和方法
CN1237102A (zh) 脂质体
JP2012505249A5 (enExample)
JP2006504653A5 (enExample)
JP2002540077A5 (enExample)
US9925252B2 (en) Antigenic compositions and methods
JP2018536002A5 (enExample)
CN1549728A (zh) 在可生物降解的微球体中含有抗原、基因载体和佐剂的免疫组合物
Wang et al. Advances of nanotechnology toward vaccine development against animal infectious diseases
JP2021042193A5 (enExample)
JP6934862B2 (ja) 抗マラリア組成物および方法
JP2004504260A5 (enExample)
Panda Nanotechnology in vaccine development
Li et al. Pattern recognition receptors and their nano-adjuvants for cancer immunotherapy
JPH05504756A (ja) 免疫刺激性を有する組成物と、そのヒトと獣医学用医薬への応用
CN118045171A (zh) 一种基于两种金属佐剂的纳米疫苗递送系统及其制备方法
Foyez et al. Nanotechnology in vaccine development and constraints
CN113226365A (zh) 纳米卫星复合物
CN116635063A (zh) 包含不影响中枢神经系统的疾病的特异性抗原和纳米颗粒的治疗性疫苗及其用途
CN114272367B (zh) 一种口服狂犬病病毒样颗粒疫苗及其制备方法